Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | March 23, 2026 | March 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date March 23, 2026 · Filed March 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 50,493 |
Reported balance
After 2026-03-23 transaction · row 1
1 source rowRow 1 · 2026-03-23 · Grant · Acquired 13,255 · Balance 50,493 F1: These shares represent a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with 1/2 of the award vesting in any one year, beginning on March 23, 2027. The award includes the right to have shares withheld for tax purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with 1/2 of the award vesting in any one year, beginning on March 23, 2027. The award includes the right to have shares withheld for tax purposes.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
EXACT SCIENCES CORP
Report date March 23, 2026 · Filed March 23, 2026
Section 16 reporting ended · disclosed 2026-03-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-23 · Grant · Acquired 53,323 · Balance 153,726 F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding. Row 2 · 2026-03-23 · Disposition to issuer · Disposed 153,726 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectHeld in 401(k) Plan | 0 |
Reported balance
After 2026-03-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-03-23 · Disposition to issuer · Disposed 1,774 · Balance 0 F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.18 | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-03-23 · Disposition to issuer · Disposed 6,581 · Balance 0 F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F4: These options became exercisable on February 14, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-03-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-23 · Disposition to issuer · Disposed 38,707 · Balance 0 F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F8: At the Effective Time, each RSU granted under an Issuer stock plan outstanding as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. F7: These RSUs vest in four equal annual installments beginning on February 25, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding.
F3: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration.
F4: These options became exercisable on February 14, 2024.
F5: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding
F6: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
F7: These RSUs vest in four equal annual installments beginning on February 25, 2027.
F8: At the Effective Time, each RSU granted under an Issuer stock plan outstanding as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerRestricted Stock Units · Derivative | 38,707 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118754 · ownership.xml · derivative · entry 5 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,707 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock. F8 · price: At the Effective Time, each RSU granted under an Issuer stock plan outstanding as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. F7 · derivative.exercise_date: These RSUs vest in four equal annual installments beginning on February 25, 2027. F7 · derivative.expiration_date: These RSUs vest in four equal annual installments beginning on February 25, 2027. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerStock Options (Right to Buy) · Derivative | 6,581 | Not disclosed Strike: $98.18 | Not disclosed |
DisclosureSEC source: 0001193125-26-118754 · ownership.xml · derivative · entry 4 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,581 shares Expires not disclosed F5 · price: At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding F4 · derivative.exercise_date: These options became exercisable on February 14, 2024. F4 · derivative.expiration_date: These options became exercisable on February 14, 2024. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 1,774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118754 · ownership.xml · nonDerivative · entry 3 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Indirect · Held in 401(k) Plan Disclosed balance after: 0 F3 · price: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Disposition to issuerCommon Stock | 153,726 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-118754 · ownership.xml · nonDerivative · entry 2 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: At the Effective Time, on the terms and subject to the conditions set forth in the Merger Agreement, each share of Common Stock, issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive the Merger Consideration. Read SEC document |
| March 23, 2026 Filed Mar 23, 2026 09:19 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 53,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-118754 · ownership.xml · nonDerivative · entry 1 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,726 F1 · shares: On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. F2 · shares: At the effective time of the Merger (the "Effective Time"), each performance based restricted stock unit ("PSU") outstanding as of immediately prior to the Effective Time was deemed to be fully vested, with any performance conditions deemed satisfied based on actual levels of achievement of applicable target levels as of November 19, 2025, and was cancelled and converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration") in respect of each share of the Issuer's common stock, par value $0.01 per share ("Common Stock") subject to such PSU, less any applicable tax withholding. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 22:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 13,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001263312-26-000004 · form4-03252026_100352.xml · nonDerivative · entry 1 ORVILLE JACOB A · CIK 0001263312 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,493 F1 · shares: These shares represent a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with 1/2 of the award vesting in any one year, beginning on March 23, 2027. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 25, 2026 Filed Feb 27, 2026 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantRestricted Stock Units · Derivative | 38,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-082839 · ownership.xml · derivative · entry 3 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,707 Underlying: Common Stock · 38,707 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on February 25, 2027. F3 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on February 25, 2027. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 16,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · derivative · entry 22 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,051 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: This award was scheduled to vest on February 25, 2026, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. F13 · derivative.exercise_date: This award was scheduled to vest in three equal installments on August 5, 2026, August 5, 2027, and August 5, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. F13 · derivative.expiration_date: This award was scheduled to vest in three equal installments on August 5, 2026, August 5, 2027, and August 5, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 28,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · derivative · entry 21 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,779 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F12 · derivative.exercise_date: This award was scheduled to vest in four equal installments on February 27, 2026, February 26, 2027, February 29, 2028, and February 28, 2029, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. F12 · derivative.expiration_date: This award was scheduled to vest in four equal installments on February 27, 2026, February 26, 2027, February 29, 2028, and February 28, 2029, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 14,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · derivative · entry 20 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,845 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F11 · derivative.exercise_date: This award was scheduled to vest in three equal installments on February 27, 2026, February 26, 2027, and February 29, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. F11 · derivative.expiration_date: This award was scheduled to vest in three equal installments on February 27, 2026, February 26, 2027, and February 29, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 9,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · derivative · entry 19 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,450 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F10 · derivative.exercise_date: This award was scheduled to vest in two equal installments on February 27, 2026 and February 26, 2027, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. F10 · derivative.expiration_date: This award was scheduled to vest in two equal installments on February 27, 2026 and February 26, 2027, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 3,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · derivative · entry 18 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,955 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F9 · derivative.exercise_date: This award was scheduled to vest on February 25, 2026, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. F9 · derivative.expiration_date: This award was scheduled to vest on February 25, 2026, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 4,426 | $101.82 | $450,655.32 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 16 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,403 F4 · shares: Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance based restricted stock units. F7 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 101,893 shares, Mr. Orville also holds, in the aggregate, an additional 6581 vested and unvested options to purchase shares of Common Stock. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 9,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 15 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,829 F6 · shares: Represents performance-based restricted share units granted to the reporting person on February 24, 2025 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2027. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 9,675 | $101.82 | $985,108.50 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 14 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,413 F4 · shares: Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance based restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 20,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 13 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,088 F5 · shares: Represents performance-based restricted share units granted to the reporting person on February 26, 2024 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2026. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 19,986 | $101.82 | $2,034,974.52 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 12 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,504 F4 · shares: Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance based restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 42,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 11 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,490 F3 · shares: Represents performance-based restricted share units granted to the reporting person on February 24, 2023 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2025. The vesting of the portion reflected herein was accelerated in order to mitigate the potential impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, on the Issuer and certain of its employees in connection with the pending transactions contemplated by the Agreement and Plan of Merger, dated November 19, 2025, by and among the Issuer, Abbott Laboratories, and Badger Merger Sub I, Inc. (the "Section 280G Mitigation"). Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 7,544 | $101.82 | $768,130.08 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 10 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,967 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 16,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 9 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 13,527 | $101.82 | $1,377,319.14 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 8 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,460 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 28,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 7 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,987 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 6,978 | $101.82 | $710,499.96 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 6 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,208 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 14,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 5 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,186 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 4,442 | $101.82 | $452,284.44 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 4 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,341 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 9,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 3 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 1,859 | $101.82 | $189,283.38 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 2 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,333 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 3,955 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-337156 · ownership.xml · nonDerivative · entry 1 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 5,000 | $75.00 | $375,000.00 |
DisclosureSEC source: 0001193125-25-291651 · ownership.xml · nonDerivative · entry 1 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,237 F1 · shares: The transaction reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on May 27, 2025. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 24,727 shares, Mr. Orville also holds, in the aggregate, an additional 79,661 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-105256 · ownership.xml · derivative · entry 4 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,051 Underlying: Common Stock · 5,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on August 5, 2024 that partially vested on August 5, 2025. The restricted stock units vest in four equal annual installments. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on August 5, 2024 that partially vested on August 5, 2025. The restricted stock units vest in four equal annual installments. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 2,515 | $46.83 | $117,777.45 |
DisclosureSEC source: 0000950170-25-105256 · ownership.xml · nonDerivative · entry 2 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,237 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 29,727 shares, Mr. Orville also holds, in the aggregate, an additional 79,661 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-105256 · ownership.xml · nonDerivative · entry 1 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:40 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 4,948 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032244 · ownership.xml · derivative · entry 7 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,845 Underlying: Common Stock · 4,948 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on February 26, 2024 that partially vested on February 28, 2025. The restricted stock units vest in four equal annual installments on the last trading day of February. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on February 26, 2024 that partially vested on February 28, 2025. The restricted stock units vest in four equal annual installments on the last trading day of February. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:40 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 4,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032244 · ownership.xml · derivative · entry 6 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 4,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: Represents a restricted stock unit award granted on February 24, 2023 that partially vested on February 28, 2025. The restricted stock units vest in four equal annual installments on the last trading day of February. F5 · derivative.expiration_date: Represents a restricted stock unit award granted on February 24, 2023 that partially vested on February 28, 2025. The restricted stock units vest in four equal annual installments on the last trading day of February. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:40 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 2,326 | $47.82 | $111,229.32 |
DisclosureSEC source: 0000950170-25-032244 · ownership.xml · nonDerivative · entry 4 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,402 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 26,892 shares, Mr. Orville also holds, in the aggregate, an additional 85,011 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:40 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 4,948 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032244 · ownership.xml · nonDerivative · entry 3 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:40 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 2,221 | $47.82 | $106,208.22 |
DisclosureSEC source: 0000950170-25-032244 · ownership.xml · nonDerivative · entry 2 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,780 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 16:40 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 4,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032244 · ownership.xml · nonDerivative · entry 1 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 20:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 3,954 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-028164 · ownership.xml · derivative · entry 5 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,955 Underlying: Common Stock · 3,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F6 · derivative.exercise_date: Represents a restricted stock unit award granted on February 25, 2022 that vests in four equal annual installments from the grant date. F6 · derivative.expiration_date: Represents a restricted stock unit award granted on February 25, 2022 that vests in four equal annual installments from the grant date. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 20:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 1,859 | $51.28 | $95,329.52 |
DisclosureSEC source: 0000950170-25-028164 · ownership.xml · nonDerivative · entry 2 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,277 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. F3 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 21,767 shares, Mr. Orville also holds, in the aggregate, an additional 94,684 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 20:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 3,954 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-028164 · ownership.xml · nonDerivative · entry 1 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 20:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantRestricted Stock Units · Derivative | 28,779 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-028164 · ownership.xml · derivative · entry 4 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,779 Underlying: Common Stock · 28,779 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F5 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on February 27, 2026. F5 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on February 27, 2026. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 2,225 | $50.48 | $112,318.00 |
DisclosureSEC source: 0000950170-25-024893 · ownership.xml · nonDerivative · entry 4 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,182 F4 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance stock units. F5 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 19,672 shares, Mr. Orville also holds, in the aggregate, an additional 69,859 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 4,805 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024893 · ownership.xml · nonDerivative · entry 3 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,407 F3 · shares: Represents shares of common stock received upon settlement of a performance share unit award. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionRestricted Stock Units · Derivative | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024893 · ownership.xml · derivative · entry 6 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F7 · derivative.exercise_date: Represents a restricted stock unit award granted on February 19, 2021 that vests in four equal annual installments from the grant date. F7 · derivative.expiration_date: Represents a restricted stock unit award granted on February 19, 2021 that vests in four equal annual installments from the grant date. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Tax withholdingCommon Stock | 1,086 | $49.63 | $53,898.18 |
DisclosureSEC source: 0000950170-25-024893 · ownership.xml · nonDerivative · entry 2 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,602 F2 · shares: Represents shares of Common Stock retained by Exact Sciences Corporation for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 16:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 2,248 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-024893 · ownership.xml · nonDerivative · entry 1 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| August 05, 2024 Filed Aug 6, 2024 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantRestricted Stock Units · Derivative | 21,401 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-092015 · ownership.xml · derivative · entry 3 ORVILLE JACOB A · CIK 0001263312 · EVP, GM, Screening 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,401 Underlying: Common Stock · 21,401 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest in four equal annual installments beginning on August 5, 2025. F3 · derivative.expiration_date: These restricted stock units vest in four equal annual installments beginning on August 5, 2025. Read SEC document |
| May 01, 2024 Filed May 2, 2024 19:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 102 | $60.15 | $6,135.30 |
DisclosureSEC source: 0000950170-24-052389 · ownership.xml · nonDerivative · entry 2 ORVILLE JACOB A · CIK 0001263312 · General Manager, Screening 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,440 F3 · shares: Represents shares sold pursuant to a Sell-to-Cover Rule 10b5-1 Plan to pay withholding taxes due in connection with the vesting of certain performance stock units. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 15,557 shares, Mr. Orville also holds, in the aggregate, an additional 50,706 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
| April 30, 2024 Filed May 2, 2024 19:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 218 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052389 · ownership.xml · nonDerivative · entry 1 ORVILLE JACOB A · CIK 0001263312 · General Manager, Screening 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,542 F1 · shares: Represents additional shares of common stock received upon settlement of a performance share unit award on April 30, 2024. F2 · balance_after: In addition to the shares of Common Stock reported on this Form 4, which total 15,557 shares, Mr. Orville also holds, in the aggregate, an additional 50,706 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.